These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15451021)

  • 1. Mutations in the carboxy-terminus of the third intracellular loop of the human recombinant VPAC1 receptor impair VIP-stimulated [Ca2+]i increase but not adenylate cyclase stimulation.
    Langer I; Robberecht P
    Cell Signal; 2005 Jan; 17(1):17-24. PubMed ID: 15451021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of inactivating mutations on phosphorylation and internalization of the human VPAC2 receptor.
    Langer I; Langlet C; Robberecht P
    J Mol Endocrinol; 2005 Apr; 34(2):405-14. PubMed ID: 15821106
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serine 447 in the carboxyl tail of human VPAC1 receptor is crucial for agonist-induced desensitization but not internalization of the receptor.
    Marie JC; Rouyer-Fessard C; Couvineau A; Nicole P; Devaud H; El Benna J; Laburthe M
    Mol Pharmacol; 2003 Dec; 64(6):1565-74. PubMed ID: 14645688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asn229 in the third helix of VPAC1 receptor is essential for receptor activation but not for receptor phosphorylation and internalization: comparison with Asn216 in VPAC2 receptor.
    Nachtergael I; Gaspard N; Langlet C; Robberecht P; Langer I
    Cell Signal; 2006 Dec; 18(12):2121-30. PubMed ID: 16650965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ac His1 [D-Phe2, K15, R16, L27] VIP (3-7)/GRF (8-27)--a VPAC1 receptor antagonist--is an inverse agonist on two constitutively active truncated VPAC1 receptors.
    Vertongen P; Langlet C; Langer I; Gaspard N; Robberecht P
    Peptides; 2004 Nov; 25(11):1943-9. PubMed ID: 15501526
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vasoactive intestinal peptide (VIP) stimulates [Ca2+]i and cyclic AMPin CHO cells expressing Galpha16.
    Langer I; Perret J; Vertongen P; Waelbroeck M; Robberecht P
    Cell Calcium; 2001 Oct; 30(4):229-34. PubMed ID: 11587546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterization of a novel VPAC(1) selective agonist and identification of the receptor domains implicated in the carboxyl-terminal peptide recognition.
    Van Rampelbergh J; Juarranz MG; Perret J; Bondue A; Solano RM; Delporte C; De Neef P; Robberecht P; Waelbroeck M
    Br J Pharmacol; 2000 Jun; 130(4):819-26. PubMed ID: 10864888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human vasoactive intestinal Peptide/Pituitary adenylate cyclase activating peptide receptor 1 (VPAC1): constitutive activation by mutations at threonine 343.
    Gaudin P; Couvineau A; Rouyer-Fessard C; Maoret JJ; Laburthe M
    Biochem Biophys Res Commun; 1999 Jan; 254(1):15-20. PubMed ID: 9920725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spatial approximation between the C-terminus of VIP and the N-terminal ectodomain of the VPAC1 receptor.
    Ceraudo E; Tan YV; Couvineau A; Lacapere JJ; Laburthe M
    Ann N Y Acad Sci; 2006 Jul; 1070():180-4. PubMed ID: 16888162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aspartate 196 in the first extracellular loop of the human VIP1 receptor is essential for VIP binding and VIP-stimulated cAMP production.
    Du K; Nicole P; Couvineau A; Laburthe M
    Biochem Biophys Res Commun; 1997 Jan; 230(2):289-92. PubMed ID: 9016768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutational analysis of the human vasoactive intestinal peptide receptor subtype VPAC(2): role of basic residues in the second transmembrane helix.
    Vertongen P; Solano RM; Perret J; Langer I; Robberecht P; Waelbroeck M
    Br J Pharmacol; 2001 Aug; 133(8):1249-54. PubMed ID: 11498510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human H9 cells proliferation is differently controlled by vasoactive intestinal peptide or peptide histidine methionine: implication of a GTP-insensitive form of VPAC1 receptor.
    Goursaud S; Pineau N; Becq-Giraudon L; Gressens P; Muller JM; Janet T
    J Neuroimmunol; 2005 Jan; 158(1-2):94-105. PubMed ID: 15589042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A small sequence in the third intracellular loop of the VPAC(1) receptor is responsible for its efficient coupling to the calcium effector.
    Langer I; Vertongen P; Perret J; Waelbroeck M; Robberecht P
    Mol Endocrinol; 2002 May; 16(5):1089-96. PubMed ID: 11981043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
    Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
    Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Site-directed mutagenesis of human vasoactive intestinal peptide receptor subtypes VIP1 and VIP2: evidence for difference in the structure-function relationship.
    Nicole P; Du K; Couvineau A; Laburthe M
    J Pharmacol Exp Ther; 1998 Feb; 284(2):744-50. PubMed ID: 9454823
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Presence of a N-terminal signal peptide in class II G protein-coupled receptors: crucial role for expression of the human VPAC1 receptor.
    Couvineau A; Rouyer-Fessard C; Laburthe M
    Regul Pept; 2004 Dec; 123(1-3):181-5. PubMed ID: 15518910
    [TBL] [Abstract][Full Text] [Related]  

  • 17. VIP differentially activates beta2 integrins, CR1, and matrix metalloproteinase-9 in human monocytes through cAMP/PKA, EPAC, and PI-3K signaling pathways via VIP receptor type 1 and FPRL1.
    El Zein N; Badran B; Sariban E
    J Leukoc Biol; 2008 Apr; 83(4):972-81. PubMed ID: 18174366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the new photoaffinity probe (Bz2-K24)-VIP.
    Tan YV; Couvineau A; Lacapere JJ; Laburthe M
    Ann N Y Acad Sci; 2006 Jul; 1070():575-80. PubMed ID: 16888228
    [TBL] [Abstract][Full Text] [Related]  

  • 19. VIP and PACAP receptor pharmacology: a comparison of intracellular signaling pathways.
    Dickson L; Aramori I; Sharkey J; Finlayson K
    Ann N Y Acad Sci; 2006 Jul; 1070():239-42. PubMed ID: 16888173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for a direct interaction between the Thr11 residue of vasoactive intestinal polypeptide and Tyr184 located in the first extracellular loop of the VPAC2 receptor.
    Nachtergael I; Vertongen P; Langer I; Perret J; Robberecht P; Waelbroeck M
    Biochem J; 2003 Mar; 370(Pt 3):1003-9. PubMed ID: 12475394
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.